1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. China Resources Pharmaceutical Group Limited
  6. News
  7. Summary
    3320   HK0000311099

CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED

(3320)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

China Resources Pharma Makes Progress on Acquisition of 30% Stake in Boya Bio

10/27/2021 | 08:03am EDT


© MT Newswires 2021
All news about CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
04/28Dong-E-E-Jiao's Profit, Revenue Rise in Q1; Shares Jump 5%
MT
04/07Everest Medicines to Form Vaccine JV With China Resources Pharmaceutical
MT
04/06Everest Medicines Enters into an MOU for Partnership with China Resources Pharmaceutica..
CI
03/29China Resources Pharmaceutical Group Seeks Mergers and Acquisitions
CI
03/29Jiangzhong Pharma Sees 15% Growth in Q1 Profit; Shares Rise 3%
MT
03/29China Resources Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended..
CI
03/29China Resources Pharmaceutical Group Limited Reports Earnings Results for the Full Year..
CI
03/22CR Boya Logs Higher Earnings in 2021; Shares Slump 6%
MT
03/14Jiangzhong Pharma Sees 11% Growth in Q1 Profit
MT
03/13China Resources Sanjiu Medical Logs Higher Preliminary Earnings in 2021
MT
More news
Financials
Sales 2022 266 B 33 873 M 33 873 M
Net income 2022 4 187 M 533 M 533 M
Net Debt 2022 39 734 M 5 062 M 5 062 M
P/E ratio 2022 6,84x
Yield 2022 3,17%
Capitalization 28 208 M 3 594 M 3 594 M
EV / Sales 2022 0,26x
EV / Sales 2023 0,23x
Nbr of Employees 65 000
Free-Float 26,3%
Chart CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
Duration : Period :
China Resources Pharmaceutical Group Limited Technical Analysis Chart | 3320 | HK0000311099 | MarketScreener
Technical analysis trends CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 4,49 HKD
Average target price 6,14 HKD
Spread / Average Target 36,8%
EPS Revisions
Managers and Directors
Xiao Song Bai Chief Executive Officer & Executive Director
Jing Wen Weng Chief Financial Officer, Executive Director & VP
Yue Wei Han Chairman
Ting Mei Fu Independent Non-Executive Director
Kin Fun Kwok Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED25.07%3 554
JOHNSON & JOHNSON6.04%477 336
PFIZER, INC.-9.55%299 678
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494